Valuation: Sanofi

Market Cap 88.53B 101B 81.57B 76.26B 143B 9,510B 146B 979B 379B 4,688B 378B 370B 16,291B P/E 2026 *
11x
P/E 2027 * 10.2x
Enterprise Value 99B 113B 91.21B 85.28B 160B 10,634B 163B 1,094B 424B 5,242B 423B 414B 18,217B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 1.9x
Free-Float
89%
Yield 2026 *
5.77%
Yield 2027 * 6.11%
Manager TitleAgeSince
Chief Executive Officer 64 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 100B
+0.93%+1.41%+44.93%+145.77% 996B
+1.61%+4.56%+60.90%+47.98% 580B
+3.51%+9.90%+31.04%+78.88% 415B
+0.99%+2.29%+27.93%+21.27% 326B
+1.34%+4.13%+32.05%+38.93% 280B
+1.09%+4.38%+36.10%+23.11% 284B
+1.32%+10.54%-30.33%-42.00% 210B
+0.40%+3.27%+27.15%+55.35% 190B
-1.05%-1.28%+15.52%+59.86% 155B
Average +1.01%+3.43%+27.25%+47.68% 381.86B
Weighted average by Cap. +1.28%+2.82%+35.65%+70.19%

Financials

2026 *2027 *
Net sales 47.07B 53.58B 43.37B 40.55B 76.05B 5,056B 77.44B 520B 202B 2,492B 201B 197B 8,662B 49.98B 56.9B 46.05B 43.06B 80.75B 5,369B 82.24B 552B 214B 2,647B 214B 209B 9,197B
Net income 8.15B 9.27B 7.5B 7.02B 13.16B 875B 13.4B 90.04B 34.88B 431B 34.82B 34.06B 1,499B 8.95B 10.19B 8.25B 7.71B 14.47B 962B 14.73B 98.99B 38.34B 474B 38.28B 37.44B 1,648B
Net Debt 10.47B 11.92B 9.64B 9.02B 16.91B 1,124B 17.22B 116B 44.82B 554B 44.75B 43.77B 1,926B 6.3B 7.17B 5.81B 5.43B 10.18B 677B 10.37B 69.65B 26.98B 334B 26.94B 26.35B 1,159B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
73.76EUR
Average target price
96.70EUR
Spread / Average Target
+31.11%

Quarterly revenue - Rate of surprise